Attention-Deficit Hyperactivity Disorder Market Forecast

Product Code DAT15313
Publication Date July 2009
Publisher Datamonitor
Product Type Interactive Model
Pages 0
ISBN Number not applicable
Change currency
PDF £9,615.00 €11,579 $15,204 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Attention-Deficit Hyperactivity Disorder Market Forecast

Introduction

Driven primarily by continued uptake of Shire's market leading ADHD drug, Adderall XR (amphetamine extended release), seven major market ADHD revenues grew strongly at a compound annual growth rate (200408) of 13.5% to reach almost $4.4 billion in 2008. Ongoing uptake of Shire's Vyvanse (lisdexamfetamine), was also a key contributor to market growth between 2007 and 2008.

Reasons to Purchase

  • This report gives a strategic analysis of the likely impact that recent events will have on the future ADHD market.
  • Includes sales forecasts for the key ADHD brands and generics as well as pipeline agents in the seven major markets to 2018.
  • Quantify the current and future size of the seven major ADHD markets.

Contents

  • Not Available